Medicines Co gains worldwide licence to Ligand's Captisol-enabled IV clopidogrel
This article was originally published in Scrip
Executive Summary
The Medicines Company has licensed worldwide rights to Ligand’s Captisol-enabled intravenous formulation of the top-selling product clopidogrel (Sanofi/Bristol-Myers Squibb's Plavix) for an upfront payment of $1.75 million.